Literature DB >> 15558578

Assessment of brain tumor angiogenesis inhibitors using perfusion magnetic resonance imaging: quality and analysis results of a phase I trial.

N Shastry Akella1, Donald B Twieg, Tom Mikkelsen, Fred H Hochberg, Stuart Grossman, Gretchen A Cloud, L Burt Nabors.   

Abstract

PURPOSE: To determine thresholds of quality for a T2*-weighted perfusion magnetic resonance imaging (MRI) study and evaluate the effects of an angiogenesis inhibitor on relative blood flow and volume changes in brain tumor patients in a multi-institution setting.
MATERIALS AND METHODS: A total of 36 volunteers from four participating institutions with clinically diagnosed malignant gliomas were studied using perfusion MRI protocols. These included a baseline study and follow-up studies every eight weeks to evaluate the effect of an anti-angiogenic agent on tumor perfusion. Quality tests were performed on the perfusion imaging data by defining statistical thresholds of acceptance. Region of interest (ROI) analysis was performed on tumors and kinetic parameters were normalized with respect to normal tissue.
RESULTS: Statistical thresholds for goodness of the gamma variate fit, T2* recovery, and mean signal full-width half-minimum (FWHMin) were computed for our data sets with a 99% one-sided confidence interval; these were 6.91%, 79.48%, and 23.35 seconds, respectively. Decreases in-blood volume and flow measurements were observed in patients with documented clinical response.
CONCLUSION: Malignant brain tumors have altered perfusion parameters that may be used to understand and monitor neovascularization. This permits non-invasive assessment of the efficacy of angiogenesis inhibiting drugs. 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15558578     DOI: 10.1002/jmri.20202

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  22 in total

1.  Correlation of volume transfer coefficient Ktrans with histopathologic grades of gliomas.

Authors:  Na Zhang; Lijuan Zhang; Bensheng Qiu; Li Meng; Xiaoyi Wang; Bob L Hou
Journal:  J Magn Reson Imaging       Date:  2012-05-11       Impact factor: 4.813

2.  ASFNR recommendations for clinical performance of MR dynamic susceptibility contrast perfusion imaging of the brain.

Authors:  K Welker; J Boxerman; A Kalnin; T Kaufmann; M Shiroishi; M Wintermark
Journal:  AJNR Am J Neuroradiol       Date:  2015-04-23       Impact factor: 3.825

Review 3.  Specific biomarkers of receptors, pathways of inhibition and targeted therapies: clinical applications.

Authors:  Y Waerzeggers; R T Ullrich; P Monfared; T Viel; M Weckesser; W Stummer; O Schober; A Winkeler; A H Jacobs
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

Review 4.  Imaging biomarkers of angiogenesis and the microvascular environment in cerebral tumours.

Authors:  G Thompson; S J Mills; D J Coope; J P B O'Connor; A Jackson
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

Review 5.  Energy failure in multiple sclerosis and its investigation using MR techniques.

Authors:  David Paling; Xavier Golay; Claudia Wheeler-Kingshott; Raju Kapoor; David Miller
Journal:  J Neurol       Date:  2011-06-10       Impact factor: 4.849

6.  Angiogenesis-independent tumor growth mediated by stem-like cancer cells.

Authors:  Per Ø Sakariassen; Lars Prestegarden; Jian Wang; Kai-Ove Skaftnesmo; Rupavathana Mahesparan; Carla Molthoff; Peter Sminia; Eirik Sundlisaeter; Anjan Misra; Berit Bølge Tysnes; Martha Chekenya; Hans Peters; Gabriel Lende; Karl Henning Kalland; Anne M Øyan; Kjell Petersen; Inge Jonassen; Albert van der Kogel; Burt G Feuerstein; A Jorge A Terzis; Rolf Bjerkvig; Per Øyvind Enger
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-20       Impact factor: 11.205

7.  Assessment of diagnostic accuracy of perfusion MR imaging in primary and metastatic solitary malignant brain tumors.

Authors:  Nail Bulakbasi; Murat Kocaoglu; Anar Farzaliyev; Cem Tayfun; Taner Ucoz; Ibrahim Somuncu
Journal:  AJNR Am J Neuroradiol       Date:  2005-10       Impact factor: 3.825

8.  Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.

Authors:  L Burt Nabors; Tom Mikkelsen; Steven S Rosenfeld; Fred Hochberg; Narasimha S Akella; Joy D Fisher; Gretchen A Cloud; Yu Zhang; Kathryn Carson; Sabine M Wittemer; A Dimitrios Colevas; Stuart A Grossman
Journal:  J Clin Oncol       Date:  2007-05-01       Impact factor: 44.544

9.  MRI-based characterization of vascular disruption by 5,6-dimethylxanthenone-acetic acid in gliomas.

Authors:  Mukund Seshadri; Michael J Ciesielski
Journal:  J Cereb Blood Flow Metab       Date:  2009-05-20       Impact factor: 6.200

10.  Effects of dexamethasone on cerebral perfusion and water diffusion in patients with high-grade glioma.

Authors:  M E Bastin; T K Carpenter; P A Armitage; S Sinha; J M Wardlaw; I R Whittle
Journal:  AJNR Am J Neuroradiol       Date:  2006-02       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.